查詢結果分析
相關文獻
- 新一代口服抗凝血劑在老年人之使用原則
- 新型口服抗凝血劑在亞洲缺血性腦中風病患之運用
- 心房顫動患者使用NOACs之臨床考量
- Sudden Cardiac Death Following Verapamil in a Patient with Wolff-Parkinson-White Syndrome and Dilated Cardiomyopathy--A Case Report and Literature Review Based on Emergency Viewpoints
- 心房顫動的最新治療
- Late Development of Persistent Atrial Fibrillation with Loss of AAI Mode Pacemaker Function and Superior Vena Cava Syndrome--Report of a Case of Sick Sinus Syndrome with Such Complications and Review of Literature
- Electrical Remodeling in Atrial Fibrillation
- 非瓣膜性心房顫動的腦中風預防
- 心房顫動病例及用藥討論
- 手術期間的心房顫動
頁籤選單縮合
| 題 名 | 新型口服抗凝血劑在亞洲缺血性腦中風病患之運用=Novel Oral Anticoagulants for Ischemic Stroke in Asia |
|---|---|
| 作 者 | 陳彥銘; 邱浩彰; | 書刊名 | 臺灣醫學 |
| 卷 期 | 23:6 2019.11[民108.11] |
| 頁 次 | 頁733-738 |
| 專 輯 | 急性腦梗塞中風處置的新進展 |
| 分類號 | 418.2321 |
| 關鍵詞 | 新型口服抗凝血劑; 心房顫動; Novel oral anticoagulants; NOACs; Atrial fibrillation; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 腦中風與心房顫動息息相關,而中風所帶來的風險也隨著亞洲的老化人口增加。在新型口服抗凝血劑問市前,warfarin已被證實可有效下降心房顫動導致的中風風險。然而,亞洲族群的獨特性使得warfarin的服藥遵從性偏低。新型口服抗凝血劑在四大研究中己被證實,對於非瓣膜性心房顫動患者是個比warfarin更好的選擇。然而,亞洲族群在標準劑量及低劑量的選擇上需要更多研究作為治療佐證,不建議常規選擇低劑量使用來預防中風。 |
| 英文摘要 | There is a close relationship between stroke and atrial fibrillation. The risk of stroke is increasing with the aging population in Asia. Warfarin had been proved to reduce the risk of cardioembolic stroke before novel oral anticoagulants (NOACs) launched. However, the drug compliance was poor because of the uniqueness of Asian ethnic groups. NOACs had been proved to be a better choice for patients of nonvalvular atrial fibrillation in the four studies included RE-LY trial, ROCKET AF trial, ENGAGE AF trial, and ARISTOTLE trial. However, we need more clinical trials to guide the treatment strategy between the choices of standard and low dosage in Asian population, and we did not recommend an unjustified underdosing. |
本系統中英文摘要資訊取自各篇刊載內容。